Thirty years as a physician and professor of medicine and pharmacology at Vanderbilt University School of Medicine and several stints as chair of FDA advisory committees exposed Alastair Wood to the challenges and pitfalls of the drug development process. Today, as managing director of Symphony Capital, a private equity firm dedicated to the biotechnology industry, Wood spends his time working to improve that process through business savvy. "Although great science may help drive a great business, great science on its own is not enough," Wood says. Click here to read about Wood and Symphony associate Sam Hall analyze a biotech business model from conception to completion.
Advertisement
Survey Series
For Advertisers
Contributors
|
|||||||||
|
|||||||||
|
